Two experiments investigated the effects of smoking status and schizotypy on the ability to gate out irrelevant information as assessed in auditory and visual latent inhibition (LI), Stroop effect and negative priming.The two experiments used 10 or 30 pre-exposures for auditory LI and a long or short interstimulus interval for the Stroop task, respectively, which included negative priming and served as masking task for the visual LI. Smoking status did not affect performance on any of the tasks, except for auditory LI after 30 pre-exposures, which was enhanced. The relationship between schizotypy and cognitive performance was complex. In Experiment 1, high schizotypals had smaller visual LI and negative priming than low schizotypals, whereas in Experiment 2 the reverse was observed, namely, larger LI and negative priming in high schizotypals.
Allan L M, Williams J H, Wellman NA, Tonin J, Taylor E, Feldon J, Rawlins J N P (1995) Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Person Individ Diff19: 893–902
2.
American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders. American Psychiatric Association Press, Washington, DC
3.
Baruch I, Hemsley D R, Gray JA (1988a) Differential performance of acute and chronic schizophrenics in latent inhibition task. J Nerv Ment Dis176: 598–606
4.
Baruch I, Hemsley D R, Gray JA (1988b) Latent inhibition and `psychotic proneness' in normal subjects. Person Individ Diff9: 777–783
5.
Beech A, Claridge G (1987) Individual differences in negative priming: relations with schizotypal personality traits. Br J Psychol78: 349–356
6.
Beech A, Baylis G C, Smithson P, Claridge G (1989) Individual differences in schizotypy as reflected in measures of cognitive inhibition. Br J Clin Psychol28: 117–129
7.
Beech A, McManus D, Baylis G, Tipper S, Agar K (1991) Individual differences in cognitive processes: towards an explanation of schizophrenic symptomatology. Br J Psychol82: 417–426
8.
Bentall R P, Claridge G S, Slade P D (1989) The multidimensional nature of schizotypal traits: a factor analytic study with normal subjects. Br J Clin Psychol28: 363–375
9.
Bullen J G, Hemsley D R, Dixon N F (1987) Inhibition, unusual perceptual experiences and psychoticism. Person Individ Diff8: 687–691
10.
Carter C S, Robertson L C, Nordahl T E (1992) Abnormal processing of irrelevant information in chronic schizophrenia: selective enhancement of Stroop facilitation. Psychiatry Res41: 137–146
11.
Chapman L J, Chapman J P, Raulin M L (1976) Scales for physical and social anhedonia. J Abnorm Psychol85: 374–382
12.
Chapman L J, Chapman J P, Raulin M L (1978) Body-image aberration in schizophrenia. J Abnorm Psychol87: 399–407
13.
Chapman L J, Chapman J P, Kwapil T R, Eckblad M, Zinser MC (1994) Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol103: 171–183
14.
Christison GW, Atwater G E, Dunn L A, Kilts C D (1988) Haloper-idol enhancement of latent inhibition: relation to therapeutic action?
15.
Biol Psychiatry23: 746–749
16.
Claridge G, Broks P (1984) Schizotypy and hemisphere function. I. Theoretical considerations and the measurement of schizotypy. Person Individ Diff5: 633–648
17.
Claridge G S (1985) The origins of mental illness. Blackwell, Oxford
18.
De La Casa L G, Lubow R E (1994) Memory for attended and nominally nonattended stimuli in low and high psychotic-prone normal subjects: The effects of test-anticipation. Person Individ Diff17: 783–789
19.
De La Casa L G, Ruiz G (1993) Latent inhibition and recall/recognition of irrelevant stimuli as a function of preexposure duration in high and low psychotic-prone normal subjects. Br J Psychol84: 119–132
20.
De La Casa L G, Ruiz G, Lubow R E (1993) Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration: implications for schizophrenia. Biol Psychiatry33: 707–711
21.
Dunn L, Atwater G, Christison G, Kilts C (1989) Latent inhibition as an animal model of antipsychotic drug action. Soc Neurosci Abstr15: 269–269
22.
Erlenmeyer-Kimling L, Cornblatt B A (1992) A summary of attentional findings in the New York High Risk Project. J Psychiatr Res26: 405–426
23.
Eysenck H J, Eysenck S B G (1975) Manual of the Eysenck personality questionnaire. Hodder and Stoughton, London
24.
Feldon J, Weiner I (1991a) An animal model of attention deficit. In Boulton A A, Baker G B, Martin-Iverson M T (eds), Neuromethods, Vol. 18: Animal models in psychiatry, pp. 313–361. Humana Press, Clifton, NJ
25.
Feldon J, Weiner I (1991b) The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats'ability to ignore irrelevant stimuli. Biol Psychiatry29: 635–646
26.
Feldon J, Weiner I (1992) From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res26: 345–366
27.
Fox E (1995) Negative priming from ignored distractors in visual selection: a review. Psychonom Bull Rev2: 145–173
28.
Franke P, Maier W, Hardt J, Hain C, Cornblatt BA (1994) Attentional abilities and measures of schizotypy: their variation and covariation in schizophrenic patients, their siblings, and normal control subjects. Psychiatry Res54: 259–272
29.
Ginton A, Urca G, Lubow R E (1975) The effects of preexposure to a nonattended stimulus on subsequent learning: latent inhibition in adults. Bull Psychonom Soc5: 5–8
30.
Gottesman I, Shields J (1982) Schizophrenia: The epigenetic puzzle. Cambridge University Press, New York
31.
Gray JA, Feldon J, Rawlins J N P, Hemsley D R, Smith A D (1991) The neuropsychology of schizophrenia. Behav Brain Sci14: 1–84
32.
Gray N S, Hemsley D R, Gray JA (1992a) Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiat Brain Res1: 83–89
33.
Gray N S, Pickering A D, Hemsley D R, Dawling S, Gray J A (1992b) Abolition of latent inhibition by a single 5 mg dose of d-ampheta-mine in man. Psychopharmacology107: 425–430
34.
Gray JA, Mitchell S N, Joseph M H, Grigoryan GA, Dawe S, Hodges H (1994) Neurochemical mechanisms mediating the behavioral and cognitive effects of nicotine. Drug Dev Res31: 3–17
35.
Gray N S, Pilowsky L S, Gray JA, Kerwin RW (1995) Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine d2 binding using SPET. Schizophr Res17: 95–107
36.
Gruzelier J, Richardson A (1994) Patterns of cognitive asymmetry and psychosis proneness. Int J Psychophysiol18: 217–225
37.
Gruzelier J H (1996) The factorial structure of schizotypy: part I. Affnities with syndromes of schizophrenia. Schizophr Bull22: 611–620
38.
Hasenfratz M, Battig K (1992) Action profiles of smoking and caffeine: Stroop effect, EEG, and peripheral physiology. Pharmacol Biochem Behav42: 155–161
39.
Hasenfratz M, Battig K (1994) Pretask smoking and smoking during a task: effects on cognitive performance, puffng behavior, physiological and subjective parameters. Hum Psycho-pharmacol9: 181–189
40.
Jacober A, Hasenfratz M, Battig K (1993) A nicotine dependent and a nicotine independent component of smoking related pulse and activity variation. Hum Psychopharmacol8: 125–132
41.
Joseph M H, Peters S L, Gray JA (1993) Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology110: 187–192
42.
Kalbfleisch J D, Prentice R L (1980) The statistical analysis of failure time data. John Wiley, New York
43.
Killcross A S, Robbins T W (1993) Differential effects of intraaccumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology106: 1–11
44.
Killcross A S, Dickinson A, Robbins T W (1994a) Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology115: 185–195
45.
Killcross A S, Dickinson A, Robbins T W (1994b) Effects of the neuroleptic a-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology115: 196–205
46.
Kwapil T R, Miller M B, Zinser MC, Chapman J, Chapman L J (1997) Magical ideation and social anhedonia as predictors of psychosis proneness: a partial replication. J Abnorm Psychol106: 491–495
47.
Lee ET (1992) Statistical methods for survival data analysis. John Wiley, New York
48.
Lenzenweger M F, Cornblatt BA, Putnick M (1991) Schizotypy and sustained attention. J Abnorm Psychol100: 84–89
49.
Lipp OV, Vaitl D (1992) Latent inhibition in human pavlovian differential conditioning: effect of additional stimulation after preexposure and relation to schizotypal traits. Person Individ Diff13: 1003–1012
50.
Lipp OV, Siddle D T, Arnold S L (1994) Psychosis proneness in a nonclinical sample II: a multi-experimental study of `attentional malfunctioning'. Person Individ Diff17: 405–424
51.
Lubow R E (1973) Latent inhibition. Psychol Bull79: 398–407
52.
Lubow R E (1989) Latent inhibition and conditioned attention theory. Cambridge University Press, New York
53.
Lubow R E, Gewirtz JC (1995) Latent inhibition in humans: data, theory, and implications for schizophrenia. Psychol Bull117: 87–103
54.
Lubow R E, Feldon J, Weiner I (1982) An animal model of attention. In Spiegelstein M Y, Levy A (eds), Behavioral models and the analysis of drug action, pp. 89–107. Elsevier, Amsterdam
55.
Lubow R E, Weiner I, Schlossberg A, Baruch I (1987) Latent inhibition and schizophrenia. Bull Psychon Soc25: 464–467
56.
Lubow R E, Ingberg-Sacks Y, Zalstein-Orda N, Gewirtz JC (1992) Latent inhibition in low and high `psychotic-prone' normal subjects. Person Individ Diff13: 563–572
57.
MacLeod C M (1991) Half a century of research on the Stroop effect: an integrative review. Psychol Bull109: 163–203
58.
Mednick SA, Schulsinger F (1968) Some premorbid characteristics related to breakdown in children with schizophrenic mothers. In Rosenthal D, Kety S S (eds), The transmission of schizophrenia, pp. 267–298. Pergamon, London
59.
Meehl PE (1962) Schizotaxia, schizotypy, schizophrenia. Am Psychol17: 827–838
60.
Neill W T, Valdes L A, Terry K M (1995) Selective attention and the inhibitory control of cognition. In Dempster F N, Brainerd C J (eds), Interference and inhibition in cognition, pp. 207–261. Academic Press, San Diego
61.
Nuechterlein K H, Dawson M E (1984a) Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull10: 160–203
62.
Nuechterlein K H, Dawson M E (1984b) Vulnerability and stress factors in the developmental course of schizophrenia disorders. Schizophr Bull10: 158–159
63.
Perkins K A, Epstein L H, Stiller R L, Marks B L, Jacob R G (1989) Chronic and acute tolerance to the heart rate effects of nicotine. Psychopharmacology97: 529–534
64.
Peters E R, Pickering A D, Hemsley D R (1994) `Cognitive inhibition' and positive symptomatology in schizotypy. Br J Clin Psychol33: 33–48
65.
Pritchard W S (1991) The link between smoking and P: a serotonergic hypothesis. Person Individ Diff12: 1187–1204
66.
Provost S C, Woodward R (1991) Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology104: 536–540
67.
Raine A (1991) The schizotypal personality questionnaire (SPQ): a scale for the measurement of schizotypal personality based on DSM-III-R criteria. Schizophr Bull17: 555–564
68.
Raine A, Sheard C, Reynolds G P, Lencz T (1992) Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophr Res7: 237–247
69.
Robbins T W (1990) The case for frontostriatal dysfunction in schizophrenia. Schizophr Bull16: 391–402
70.
Rochford J, Sen A P, Quirion R (1996) Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. J Pharmacol Exp Therapeut277: 1267–1275
71.
Siever L J (1994) Biologic factors in schizotypal personality disorders. Psych Scand90: 45–50
72.
Siever L J, Kalus OF, Keefe R S E (1993) The boundaries of schizophrenia. Psychiatr Clin North Am16: 217–245
73.
Solomon P R, Crider A, Winkelman J W, Turi A, Kamer R M, Kaplan L J (1981) Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relation-ship to schizophrenic attention disorder. Biol Psychiatry16: 519–537
74.
Stroop J R (1935) Studies of interference in serial verbal reactions. J Exp Psychol18: 643–662
75.
Suter T W, Buzzi R, Woodson P P, Battig K (1983) Psychophysiological correlates of conflict solving and cigarette smoking. Activ Nerv Sup25: 261–272
76.
Swerdlow N R, Filion D, Geyer M A, Braff D L (1995) `Normal' personality correlates of sensorimotor, cognitive, and visuospatial gating. Biol Psychiatry37: 286–299
77.
Swerdlow N R, Braff D L, Hartston H, Perry W, Geyer M A (1996) Latent inhibition in schizophrenia. Schizophr Res20: 91–103
78.
Thornton JC, Dawe S, Lee C, Capstick C, Corr PJ, Cotter P, Frangou S, Gray N S, Russell M A H, Gray JA (1996) Effects of nicotine and amphetamine on latent inhibition in human subjects. Psycho-pharmacology127: 164–173
79.
Tipper S P (1985) The negative priming effect: inhibitory effects of ignored primes. Quart J Exp Psychol37A: 139–154
80.
Tyrka A R, Cannon T D, Haslam N, Mednick SA, Schulsinger F, Schulsinger H, Parnas J (1995) The latent structure of schizotypy: I. Premorbid structure of a taxon of individuals at risk for schizophrenia-spectrum disorders. J Abnorm Psychol104: 173–185
81.
Vollema MG, Van den Bosch R J (1995) The multidimensionality of schizotypy. Schizophr Bull21: 19–31
82.
Warburton EC, Joseph M H, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced disruption of LI in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology114: 657–664
83.
Weiner I (1990) Neural substrates of latent inhibition: the switching model. Psychol Bull108: 442–461
84.
Weiner I, Feldon J (1987) Facilitation of latent inhibition by halo-peridol in rats. Psychopharmacology91: 248–253
85.
Weiner I, Feldon J (1997) The switching model of latent inhibition: an update of neural substrates. Behav Brain Res88: 11–25
86.
Weiner I, Lubow R E, Feldon J (1981) Chronic amphetamine and latent inhibition. Behav Brain Res2: 285–286
87.
Weiner I, Lubow R E, Feldon J (1984) Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology83: 194–199
88.
Weiner I, Feldon J, Katz Y (1987) Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav26: 241–246
89.
Weiner I, Lubow R E, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav30: 871–878
90.
Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996) The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic clozapine. Biol Psychiatry40: 834–843
91.
Weiner I, Shadach E, Barkai R, Feldon J (1997) Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology16: 42–50
92.
Wesnes K, Warburton DM (1978) The effects of cigarette smoking and nicotine tablets upon human attention. In Thornton R E (ed.), Smoking behaviour, pp. 131–147. Churchill Livingstone, Edinburgh
93.
Wesnes K, Warburton DM (1983) Smoking, nicotine and human performance. Pharmacol Ther21: 189–208
94.
Williams L M (1995) Further evidence for a multidimensional personality disposition to schizophrenia in terms of cognitive inhibition. Br J Clin Psychol34: 193–213
95.
Williams J H, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins J N P (1996) Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biol Psychiatry40: 1135–1143
96.
Williams J H, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins J NP (1997) Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology133: 262–268
